Response

Affiliations

¹ Oncology Department, Hospital de la Santa Creu i Sant Pau and Universitat Autònoma de Barcelona, Barcelona, Spain.
² Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre and the University of Toronto, Toronto, Ontario, Canada.

Comment

Ariadna Tibau et al. J Natl Cancer Inst. 2018.

. 2018 Oct 1;110(10):1145.

doi: 10.1093/jnci/djy031.

¹ Oncology Department, Hospital de la Santa Creu i Sant Pau and Universitat Autònoma de Barcelona, Barcelona, Spain.
² Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre and the University of Toronto, Toronto, Ontario, Canada.

No abstract available

Comment on

Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration.
Tibau A, Molto C, Ocana A, Templeton AJ, Del Carpio LP, Del Paggio JC, Barnadas A, Booth CM, Amir E. Tibau A, et al. J Natl Cancer Inst. 2018 May 1;110(5):486-492. doi: 10.1093/jnci/djx232. J Natl Cancer Inst. 2018. PMID: 29244173
RE: Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration.
Cherny NI, Dafni U, Bogaerts J, Latino NJ, Pentheroudakis G, Douillard JY, Tabernero J, Zielinski C, Piccart MJ, de Vries EGE. Cherny NI, et al. J Natl Cancer Inst. 2018 Oct 1;110(10):1142-1143. doi: 10.1093/jnci/djy029. J Natl Cancer Inst. 2018. PMID: 29546378 No abstract available.